( 您好!臺灣時間:2021/05/11 12:11
字體大小: 字級放大   字級縮小   預設字形  


研究生(外文):Szu-Yao Kuo
論文名稱(外文):Identification of Oral Cancer-Targeted Peptides by in vivo Phage Display and Development of Ligand-Targeted Therapy for Oral Cacncer
外文關鍵詞:oral cancer-targeted peptide
  • 被引用被引用:1
  • 點閱點閱:156
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
利用活體的噬菌體顯現法技術可以篩選出與腫瘤組織專一性結合的標的胜肽。在此研究中,我們已經利用活體噬菌體顯現法尋找出一些可以和口腔癌腫瘤組織結合之胜肽。運用此方法所找到數個噬菌體株,與口腔癌組織結合的能力分別高於普通組織約12到40倍。控制組的噬菌體株,則不具有與腫瘤組織專一性結合的能力。當我們將所篩選到的噬菌體株 (IVO-2 phage) 與其相對應的胜肽 (PIVO-2 peptide) 去做競爭性抑制實驗,可以看出IVO-2 噬菌體株與口腔癌組織結合的能力可以被合成胜肽PIVO-2明顯的抑制下來。為了證明這段專一性與腫瘤組織結合的胜肽,可以增進口腔癌的治療效果,以達到標的治療的目的,我們也將PIVO-2連結微脂體包�厤oxorubicin抗癌藥物 (LD-PIVO-2) 和單一只有此抗癌藥物 (LD) 來進行抗癌療效的比較。結果顯示,含有標的胜肽連結抗癌藥物LD-PIVO-2處理過後的老鼠,治療效果最佳 (存活率100%),口腔癌腫瘤明顯小於只有抗癌藥物 (LD) 處理後的老鼠 (存活率33.3%)。由此結果得知標的胜肽PIVO-2可以增進口腔癌的治療效果,並具有臨床發展標的治療的潛力。
另外,我們也將RGD 胜肽 (P1 peptide) 及angiostatin (Ag) 分別連結於抗癌藥物 (LD),並運用於癌症上的治療。在老鼠的實驗中,我們發現含有angiostatin或RGD胜肽的抗癌藥物除了療效極佳之外,也確實可降低藥物的毒性,減少藥物的副作用。因此,P1-LD 或Ag-LD可以提供作為口腔癌或其它癌症標的治療或抑制腫瘤血管新生治療的一種新穎的治療方向。
Oral cancer is a common cancer among Chinese living and ranks fourth in the mortality rate of male cancer patients in Taiwan. Cytotoxic chemotherapy or radiotherapy is major treatment as cancer therapies and is limited by serious side effects because therapies are not selective for malignant cells. Ligand-targeted therapy affords tumor specificity and limited toxicity and will promise new therapies to treat oral cancer.
In vivo phage display is a powerful tool for the discovery of ligands that selectively home to tumor. In this study, we used this method to identify specific peptides that could home to the Severe combined immunodeficiency (SCID) mice bearing oral cancer xenograft. Several phage clones selected in this manner homed to the oral cancer 12–40 times more than to control organs. Unselected control phage did not show this preference. Synthetic peptide PIVO-2, corresponded to IVO-2 phage displayed peptide sequence, was shown to inhibit the homing activity completely when co-injected into mice with the phage. To determine the efficacy of the tumor-homing peptide PIVO-2 for improvement the therapeutic index, systemic treatment of oral cancer bearing mice with doxorubicin-loaded liposome (LD) and peptide-conjugated LD (LD-PIVO-2) was performed. The mice showed significantly smaller tumor mass when we treated with the LD-PIVO-2 than LD only. LD-PIVO-2 treated mice have 100% survival rate but LD treated mice only have 33.3% survival rate. These results indicate that PIVO-2 peptide enhanced the efficacy of the drug against oral cancer xenografts in SCID mice and suggest that this peptide has a strong clinical potential for drug delivery guider to treat oral cancer.
We also developed ligand-targeted therapy using LD conjugated to angiostatin and RGD peptide. We found that the conjugation of LD with angiostatin or RGD peptide decrease the toxicity of cancer therapy to the tumor-bearing mice. This approach may provide a new strategy for the purpose of ligand-targeted therapy or anti-angiogenic therapy for solid tumors.
Materials and methods..19
Ahmad, I., Longenecker, M., Samuel, J., and Allen, T.M. (1993). Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 53, 1484-1488.
Allen, T.M. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750-763.
Allman, R., Cowburn, P., and Mason, M. (2000). In vitro and in vivo effects of a cyclic peptide with affinity for the αvβ3 integrin in human melanoma cells. Eur. J. Cancer 36, 410-422.
Arap, W. et al. (2002). Steps toward mapping the human vasculature by phage display. Nat. Med. 8, 121-127.
Arap, W. et al. (2002). Targeting the prostate for destruction through a vascular address. PNAS 99, 1527-1531.
Arap, W., Pasqualini, R. and Ruoslahti, E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377–380.
Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai, Y., Silver, M., and Isner, J.M. (1999). VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18, 3964-3972.
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., chatteman, G., and Isner, J.M. (1997). Isolation of Putative Progenitor Endothelial Cells for Angiogenesis. Science 275, 964-967.
Asai, T., Kurohane, K., Shuto, S., Awano, H. Matsuda, A., Tsukada, H., Namba, Y., Okada, S., and Oku, N. (1998). Antitumor Activity of 5''-O-Dipalmitoylphosphatidyl
2''-C-Cyano-2''-deoxy-1-bD-arabiono-pento-furanosylcytosine Is Enhanced by Long-circulating Liposomalization. Biol. Pharm. Bull. 21, 766-771.
Augustin, H.G., Kozian, D.H., and Johnson, R.C. (1994). Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioassays 16, 901–906.
Balazosovits, J.A., Mayer, L.D., Bally, M.B., Cullis, P.R., Mcdonell, M., Ginsberg, R.S., and Falk, R.E. (1989). Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxoribicin. Cancer Chemother. Pharmacol. 23, 81-86.
Barry, M.A., Dower, W.J., and Johnston, S.A: (1996). Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat. Med. 2, 299-305.
Baselga, J. (2001). Clinical trials of Herceptin (trastuzumab). Eur. J. Cancer 37 (suppl. 1), 18–24.
Bhagwat, S.V., et al. (2001). CD31/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 97, 652-659.
Boehm, T., Folkman, J., Browder, T., and MS, O.R. (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407.
Bono, D.P., and Green, C. (1984). The adhesion of different cell types to cultured vascular endothelium: effects of culture density and age. Brit. J. Exp. Pathol. 65, 145–154.
Borsum, T., Hagen, I., Henriksen, T., and Carlander, B. (1982). Alterations in the protein composition and surface structure of human endothelial cells during growth in primary culture. Atherosclerosis 44, 367–378.
Brooks, P.C. et al. (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin avb3. Cell 85, 683–693.
Brooks, P.C., Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G., and Cheresh, D.A. (1994). Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164.
Brooks, P.C., Stromblad, S., Klemke, R., Visscher, D., Sarkar, F.H., and Cheresh, D.A. (1995). Anti-integrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815-1822.
Browder, T., Butterfield, C.E., Kraling, B.M., Shi, B., Marshall, B., O''Reilly, M.S. and Folkman, J. (2000). Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer. Cancer Res. 60, 1878-1886.
Brown, J.M., and Giaccia, A.J. (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416.
Burg M.A., Pasqualini R., Arap W., Ruoslahti E., and Stallcup, W.B. (1999). NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res. 59, 2869–2874.
Burrows, and Thorpe, P.E. (1994). Vascular targeting--a new approach to the therapy
of solid tumors. Pharmacol. Ther. 64, 155-174.
Burrows, F.J., and Thorpe, P.E. (1993). Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA 90, 8996-9000.
Carmeliet, P., and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
Carswell, E.A. et al. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666–3670.
Chen, Y. et al. (2001). RGD-Tachyplesin inhibits tumor growth. Cancer Res. 61, 2434-2438.
Choo, Y., and Klug, A. (1995). Designing DNA-binding proteins on the surface of filamentous phage. Curr. Opin. Biotechnol. 6, 431-436.
Clauss, M. et al. (1990). A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J. Biol. Chem. 265, 7078–7083.
Corti, A. & Marcucci, F. (1998). Tumour necrosis factor: strategies for improving the therapeutic index. J. Drug Targ. 5, 403–413.
Cotran, R.S., Kumar, V., and Collins, T. (1999) Robbins Pathological Basis of Disease (Saunders, Philadelphia), 6th Ed.
Curnis, F. et al. (2000). Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18, 1185-1190.
Curnis, F. et al. (2002). Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 62, 867-874.
Cwirla, S. E., Peters, E. A., Barrett, R. W., and Dower, W. J. (1990). Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Science USA 87, 6378-6382.
D’ Arpa, P., and Liu, L.F. (1989). Topoisomerase-targeting antitumor drugs. Biochem. Biophys. Acta. 989, 163-177.
Denekamp, J. (1993). Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol. 66, 181-196.
Devlin, J.J., Panganiban, L.C., and Devlin, P.E. (1990). Random peptide libraries: a source of specific protein binding molecules. Science 249, 404-406.
Dong, Z., Kumar, R., Yang, X., and Fidler, I.J. (1997). Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88, 801-810.
Drummond, D C., Meyer, O., Hong, K., Kirpotin, D.B., and Papahadjopoulos, D. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51, 691-743.
Eggermont, A.M. et al. (1996). Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol. 14, 2653–2665.
Ellerby, H.M. et al. (1999). Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5, 1032-1038.
Essler M. And Ruoslahti E. (2002). Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. PNAS 99, 2252-2257.
Fiers, W. (1995). Biologic therapy with TNF: preclinical studies In Biologic therapy of cancer: principles and practice. (eds DeVita, V., Hellman, S., and Rosenberg, S.) (Lippincott and Philadelphia) 295–327.
Folkman, J. (1997). In cancer: principles and practice of oncology. (eds. DeVita, V.T., Hellman, S., and Rosenberg, S.A.) 3075-3087 (Lippincott-Raven, New York).
Forrer, P., Jung, S., and Pluckthun, A. (1999). Beyond binding: Using phage display to select for structure, folding and enzymatic activity in proteins. Curr. Opin. Struct. Biol. 9, 514-520.
Forssen, E.A., and Tokes, Z.A. (1979). In vitro and in vivo studies with adriamycin liposomes. Biochem. Biophys. Res. Commun. 91, 1295-1301.
Fraker, D.L., Alexander, H.R., and Pass, H.I. (1995). Biologic therapy with TNF: systemic administration and isolation perfusion. In Biologic therapy of cancer: principles and practice. (eds De Vita, V., Hellman, S., and Rosenberg, S.) (J.B. Lippincott, Philadelphia), 329–345.
Fraker, D.L., Alexander, H.R., Andrich, M., and Rosenberg, S.A. (1996). Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J. Clin. Oncol. 14, 479–489.
Frank, D.H., and Clayman, G.L. (2000). Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Res. 60, 6551-6556.
Frederick, C.A., Williams, L.D., Ughetto, G. van der Marel, G.A. van Boom, J.H., Rich, A., and Wang, A.H.J. (1990). Structural comparison of anticancer drug-DNA complexes: Adriamycin and Daunomycin. Biochemistry 29, 2538-2549.
Gabizon, A., Dagan, A., Goren, D., Barenholz, Y., and Fuks, Z. (1982). Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 42, 4734-4739.
Gabizon, A., Goren, D., Fuks, Z., Meshoren, A., and Barenholz, Y. (1985). Superior therapeutic acitvity of liposome-associated adriamycin in a murine metastatic tumour model. Br. J. Cancer 51, 681-689.
Gasparri, A. et al. (1999). Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models. Cancer Res. 59, 2917–2923.
Gately, S., Twardowski, P., Stack, M.S., Cundiff, D.L., Grella, D.,Castellino, F.J., Enghild, J., Kwaan, H.C., Lee, F., Kramer, R.A., Volpert, O., Bouck, N., and Soff, G.A. (1997). The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Nat. Acad. Sci. USA 94, 10868-10872.
Gately, S., Twardowski, P., Stack, M.S., Patrick, M., Boggio, L., Cundiff, D.L., Schnaper, H.W., Madison, L., Volpert, O., Bouck, N., Enghild, J., Kwaan, H.C., and Soff, G.A. (1996). Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56, 4887-4890.
Gullick, W.J. et al. (1985). The structure and function of the epidermal growth factor receptor studied by using antisynthetic peptide antibodies. Proc. R. Soc. Lond. B. Biol. Sci. 226, 127-134.
Haas, T.L., Davis, S.J. and Madri, J.A. (1998). Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J. Biol. Chem. 273, 3604–3610.
Hallahan, D. et al. (2003). Intergrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 3, 63-74.
Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364.
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
Haubner, R., Wester, H.J., Weber, W.A. Mang, C., Ziegler, S.I., Goodman, S.L., Senekowitsch-Schmidtke, R., Kessler, H., and Schwaiger, M. (2001). Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61, 1781-1785.
Heppner, K.J., Matrisian, L.M., Jensen, R.A. & Rodgers, W.H. (1996) Expression of most matrix metalloproteinase family members in breast cancer represents a tumor induced response. Am. J. Pathol. 149, 273–282.
Hoekman, K., van der vijgh, W.J.A., and Vermorken, J.B. (1999). Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Drugs 57, 133-155.
Hoffman J.A., Giraudo, E., Singh, M., Zhang, L., Inoue, M., Porkka, K., Hanahan, D., and Ruoslahti, E. (2003). Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 4, 383-391.
Hong, F.D., and Clayman, G.L. (2000). Isolation of apeptide for targeted drug delivery into human head and neck solid tumors. Cancer Res. 60, 6551-6556.
Huang, S.K., Mayhew, E., Gilani, S., Lasic, D.D., Martin, F.J., and Papahadjopoulos, D. (1992). Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52, 6774–6781.
Huang, X., Molema, G., King, S., Watkins, L., Edgington, T.S., and Thorpe, P.E. (1997). Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275, 547-550.
Ito, H., Rovira, I.I., Bloom, M.L., Takeda, K., Ferrans, V.J., Quyyumi, A.A., and Finkel., T. (1999). Endothelial Progenitor Cells as Putative Targets for Angiostatin. Cancer Res. 59, 5875-5877.
Izumi, Y., Xu, L., and Tomaso, E. et al. (2002). Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279–80.
Jain, R.K. (1996). Delivery of molecular medicine to solid tumors. Science 271, 1079–1080.
Joyce, J.A., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E., and Hanahan, D. (2003). Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4, 393-404.
Julian, A., and Kim, M.D. (2003). Targeted therapies for the treament of cancer. The American J. of Surgery 186, 264-268.
Karakiulakis, G. et al. (1997) Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion and Metastasis 17, 158–168.
Kerbel, R.S. (1997). A cancer therapy resistant to resistance. Nature 390, 335-336.
Koivunen, E. et al. (1999). Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17, 768–774.
Koivunen, E., Wang, B. and Ruoslahti, E. (1995). Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Bio. Technology 13, 265–270.
Kolonin, M.G., Saha, P.K., Chan, L., Pasqualini, R., and Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nat. Med. 10, 625-632.
Laakkonen, P., Porkka, K., Hoffman, J.A., and Ruoslahti, E. (2002). A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nature Med. Advance online publication, 1-4.
Ladner, R.C. (1999). Polypeptides from phage display. A superior source of in vivo imaging agents. Q. J. Nucl. Med. 43, 119-124.
Langer, R. (1998). Survey results boost calls for new teaching efforts. Nature 392, 5-10.
Leibowitz, S.F. (1995). Brain peptides and obesity: pharmacologic treatment. Obes. Res. 3, 573-589.
Levitan, B. (1998). Stochastic modeling and optimization of phage display. J. Mol. Biol. 277, 893-916.
Liekens, S., De Clercq, E., and Neyts, J. (2001). Angiogenesis: regulator and clinical applications. Biochem. Pharmacol. 61, 253-270.
Lienard, D., Ewalenko, P., Delmotte, J.J., Renard, N., and Lejeune, F.J. (1992). High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10, 52–60.
Lijnen, H.R., Ugwu, F., Bini, A., and Collen, D. (1998). Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemsitry 37, 4699-6702.
Liotta, L.A. et al. (1980) Metastatic potential correlates with enzyme derived from a metastatic murine tumor. Nature 284, 67–68.
Martin, F.J., and Papahadjopoulos, D. (1982). Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J. Biol. Chem. 257, 286-288.
Matsumura, Y., and Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46, 6387-6392,
Mayer, L.D., Tai, L.C.L., Bally, M.B., Mitilenes, G.N., Ginsberg, R.S., and Cullis, P.R. (1990). Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochem. Biophys. Acta. 1025, 143-151.
Mayer, L.D., Tai, L.C.L., Ko, D.S.C., Masin, D., Ginsberg, R.S., Cullis, P.R., and Bally, M.B. (1989). Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res., 49, 5922–5930.
Murphy, G., and Crabbe, T. (1995). Gelatinases A and B. Methods Enzymol. 248, 470–484.
Naoto, O. et al. (2002). Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 21, 2662-2669.
Nawroth, P. et al. (1988). Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med. 168, 637–647.
Nawroth, P.P. & Stern, D.M. (1986). Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163, 740–745.
Oku, N. (1999). Anticancer therapy using glucuronate modified long-circulating liposomes. Adv. Drug Deliv. Rev. 40, 63-73.
O''Reilly, M.S., Holmgren, L., Chen, C., and Folkman, J. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2, 689- 692.
O''Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H., and Folkman, J. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
Palladino, M.A. Jr. et al. (1987). Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol. 138, 4023–4032.
Papahadjopoulos, D., Allen, T.M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S.K., Lee, K.D., Woodle, M.C., Lasic, D.D., Redemann, C., and Martin, F.J. (1991). Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88, 11460-11464.
Parmley, S. F., and Smith, G. P. (1988). Antibody-selectable filamentous fd phage vectors: affinity purification fo target genes. Gene 73, 305-318.
Pasqualini, R., and Ruoslahti, E. (1996). Organ targeting in vivo using phage display peptide libraries. Nature 380, 364-366.
Pasqualini, R. et al. (2000). Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60, 722–727.
Pasqualini, R., Arap, W., Rajotte, D. and Ruoslahti, E. (1999) in Phage display of proteins and peptides (eds Barbas, C., Burton, D., Silverman, G., & Scott, J.) (Cold Spring Harbor Laboratory Press, New York). In press.
Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1997). Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542–546.
Pegram, M., Hsu, S., Lewis, G. et al. (1999). Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancer. Oncogene 18, 2241-2251.
Plow, E.F., Haas, T.A., Zhang, L., Loftus, J., and Smith, J.W. (2000). Ligand binding to integrins. J. Biol. Chem. 275, 21785-21788.
Porkka, K., Laakkonen, P., Hoffman, J.A., Bernasconi, M., and Ruoslahti, E. (2002). A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. USA 99, 7444–7449.
Press, M.F. et al. (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in mode-negative breast carcinomas. J. Clin. Oncol. 15, 2894-2904.
Pyke, C., Ralfkiaer, E., Tryggvason, K., and Dano, K. (1993). Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am. J. Pathol. 142, 359–365.
Rahman, A., Kessler, A., More, N., Sikic, B., Rowden, G., Woolley, P., and Schein, P.S. (1980). Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 40, 1532-1537.
Rajotte, D., and Ruoslahti, E. (1999). Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J. Biol. Chem. 274, 11593-11598.
Rajotte, D., Arap, W., Hagedorn, M., Koivunen, E., Pasqualini, R., and Ruoslahti, E. (1998). Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest. 102, 430-437.
Ruoslahti, E. (1996). RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697-715.
Ruoslahti, E. (2002). Specialization of tumor vasculature. Nat. Rev. Can. 2, 83-90. Kolonin, M., Pasqualini, R., and Arap, W. (2001). Molecular addresses in blood vessels as targets for therapy. Curr. Opin. Chem. Bio. 5, 308-313.
Ruoslahti, E., and Pierschbacher, M.D. (1987). New perspectives in cell adhesion: RGD and integrins. Science 238, 491-497.
Ruoslahti, E., and Rajotte, D. (2000). An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol. 18, 813-827.
Scott, J. K., and Smith, G.P. (1990). Searching for peptide ligands with an epitope library. Science 249, 386-390.
Sinil, K. (1993). Liposomes as carriers fo cancer chemotherapy-current status and future prospects. Drugs 46, 618-638.
Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., and Fusenig, N.E. (1997). Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 3, 1222 -1227.
Smith, G. P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315-1317.
Smith, G.P., and Petrenko, V.A. (1997). Phage display. Chem. Rev. 97, 391-410.
Smith, G.P., and Scott, J.K. (1993). Libraries of peptides and proteins displayed on filamentous phage. Methods in Enzymol. 217, 228–257.
Smothers, J.F., Henikoff, S., and Carter, P. (2002). Affinity selection from biological libraries. Science 298, 621-622.
St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K.E., Montgomery, E., Lal, A., Riggins, G.J., Lengauer, C., Vogelstein, B., and Kinzler, K.W. (2000). Genes expressed in human tumor endothelium. Science 289, 1197-1202.
Stathakis, P., Fitzgerald, M., Matthias, L.J., Chesterman, C.N., and Hogg, P.J. (1997). Generation of angiostatin by reduction and proteolysis of plasma. Catalysis by a plasmin reductase secreted by cultured cells. J. Biol. Chem. 272, 20641-20645.
Storm, G., Roerdink, F.H., Steerenberg, P.A., de Jong, W.H., and Crommelin, D.J.A. (1987). Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing lipidsomes in a rat solid tumor model. Cancer Res. 47, 3366-3372.
Sugiura, Y., Shimada, H., Seeger, R.C., Laung, W.E., and DeClerck, Y.A. (1998) Matrix metalloproteinases- 2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 58, 2209–2216.
Tardi, P.G., Boman, N.L., and Cullis, P.R. (1996). Liposomal doxorubicin. J. drug target 4, 129-140.
Trepel, M., Arap, W., and Pasqualini, R. (2002). In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr. Opin. in Chem. Biol. 6, 399-404.
Trepel, M., Grifman, M., Weitzman, M.D., and Pasqualini, R. (2000). Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum. Gene Ther. 11, 1971-1981.
Van Hagen, P.M., Breeman, W.A., Bernard, H.F. Schaar, M., Mooij, C.M., Srinivasan, A., Schmidt, M.A. Krening, E.P., and de Jong, M. (2000). Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumor inaging and radionuclide therapy. Int. J. Cancer 90, 186-198.
Vant-Hull, B., Payano-Baez, A., Davis, R.H., and Gold, L. (1998). The mathematics of SELEX against complex targets. J. Mol. Biol. 278, 579-597.
Viti, F., Tarli, L., Giovannoni, L., Zardi, L., and Neri, D. (1999). Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumor angiogenesis. Cancer Res. 59, 347-352.
Vu, T.H. et al. (1998). MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93, 411–422.
Wilhelm, S.M. et al. (1989). SV40-transformed human lung fibroblasts secrete a 92 kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 264, 17213–17221.
Yamamoto, M., Kominato, Y., and Yamamoto, F. (1999). Phage display cDNA
cloning of protein with carbohydrate affinity. Biochem. Biophys. Res. Commun. 255, 194-199.
Zitzmann, S., Ehemann, V., and Schwab, M. (2002). Arginine-Glycine-Aspartic Acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 62, 5139-5143.
Zwick, M.B., Shen, J., and Scott, J.K. (1998). Phage-displayed peptide libraries. Curr. Opin. in Biotechnol. 9, 427-436.
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔